Skip to main content

ClearPlasma is an innovative medical device that enhances coagulation properties for improved treatment of excessive bleeding.

Project description

Medical innovation to prevent blood loss by enhancing coagulation

Massive loss of blood can occur upon trauma, surgery, childbirth, disseminated intravascular coagulation, gastrointestinal bleeding, etc. Recent studies have shown that urgent transfusion of regular plasma fails to stop massive bleeding, while other treatments are less efficient and result in increased mortality risk. The EU-funded ClearPlasma project is developing an innovative filtration system which modifies human plasma and improves the treatment of massive bleeding and bleeding disorders. The filtration extracts plasminogen, a critical protein component responsible for dissolving blood clots, enhancing coagulation and improving haemostasis, which significantly reduces bleeding. ClearPlasma is a disposable filter that can be incorporated in current clinical practices using apheresis systems. Current phase 1 of the project advances the broad development plan.

Call for proposal

H2020-EIC-SMEInst-2018-2020

See other projects for this call

Sub call

H2020-SMEInst-2018-2020-1

Coordinator

PLAS-FREE LTD
Net EU contribution
€ 50 000,00
Address
Wadi El Haj 13
1600101 Nazareth
Israel

See on map

Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Other funding
€ 21 429,00